{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T11:00:04Z","timestamp":1777114804982,"version":"3.51.4"},"publisher-location":"New York, NY","reference-count":31,"publisher":"Springer US","isbn-type":[{"value":"9781071644416","type":"print"},{"value":"9781071644423","type":"electronic"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1007\/978-1-0716-4442-3_18","type":"book-chapter","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T13:15:00Z","timestamp":1741007700000},"page":"269-297","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Generation and Reactivity Profiling of Functional Human Recombinant Monoclonal Antibodies"],"prefix":"10.1007","author":[{"given":"Anastasia","family":"Iatrou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Fitopoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Agathangelidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,4]]},"reference":[{"issue":"7","key":"18_CR1","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R et al (2022) The 5th edition of the World Health Organization classification of Haematolymphoid tumours: lymphoid neoplasms. Leukemia 36(7):1720\u20131748","journal-title":"Leukemia"},{"issue":"11","key":"18_CR2","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1182\/blood.2022015851","volume":"140","author":"E Campo","year":"2022","unstructured":"Campo E et al (2022) The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee. Blood 140(11):1229\u20131253","journal-title":"Blood"},{"issue":"8","key":"18_CR3","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nrc3774","volume":"14","author":"DW Scott","year":"2014","unstructured":"Scott DW, Gascoyne RD (2014) The tumour microenvironment in B cell lymphomas. Nat Rev Cancer 14(8):517\u2013534","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"18_CR4","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.3324\/haematol.2014.119933","volume":"100","author":"E Fonte","year":"2015","unstructured":"Fonte E et al (2015) Toll-like receptor stimulation in splenic marginal zone lymphoma can modulate cell signaling, activation and proliferation. Haematologica 100(11):1460\u20131468","journal-title":"Haematologica"},{"issue":"2","key":"18_CR5","first-page":"89","volume":"5","author":"CJ Oquendo","year":"2021","unstructured":"Oquendo CJ, Parker H, Oscier D, Ennis S, Gibson J, Strefford JC (2021) The (epi)genomic landscape of splenic marginal zone lymphoma, biological implications, clinical utility, and future questions. J Transl Genet Genomics 5(2):89\u2013111","journal-title":"J Transl Genet Genomics"},{"key":"18_CR6","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1146\/annurev.immunol.23.021704.115728","volume":"23","author":"S Pillai","year":"2005","unstructured":"Pillai S, Cariappa A, Moran ST (2005) Marginal zone B cells. Annu Rev Immunol 23:161\u2013196","journal-title":"Annu Rev Immunol"},{"key":"18_CR7","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1038\/leu.2012.207","volume":"26","author":"V Bikos","year":"2012","unstructured":"Bikos V et al (2012) Selection of antigen receptors in splenic marginal-zone lymphoma: further support from the analysis of the immunoglobulin light-chain gene repertoire. Leukemia 26:2567\u20132569","journal-title":"Leukemia"},{"issue":"12","key":"18_CR8","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.1182\/blood-2011-03-341651","volume":"118","author":"AA Warsame","year":"2011","unstructured":"Warsame AA et al (2011) Splenic marginal zone lymphoma with VH1-02 gene rearrangement expresses poly- and self-reactive antibodies with similar reactivity. Blood 118(12):3331\u20133339","journal-title":"Blood"},{"issue":"1","key":"18_CR9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","volume":"17","author":"S Pal Singh","year":"2018","unstructured":"Pal Singh S, Dammeijer F, Hendriks RW (2018) Role of Bruton\u2019s tyrosine kinase in B cells and malignancies. Mol Cancer 17(1):57","journal-title":"Mol Cancer"},{"issue":"3","key":"18_CR10","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/nrc.2017.121","volume":"18","author":"JA Burger","year":"2018","unstructured":"Burger JA, Wiestner A (2018) Targeting B cell receptor signalling in cancer: preclinical and clinical advances. Nat Rev Cancer 18(3):148\u2013167","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"18_CR11","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S1470-2045(14)70335-3","volume":"15","author":"JA Burger","year":"2014","unstructured":"Burger JA et al (2014) Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol 15(10):1090\u20131099","journal-title":"Lancet Oncol"},{"issue":"3","key":"18_CR12","doi-asserted-by":"publisher","first-page":"403","DOI":"10.4161\/mabs.19909","volume":"4","author":"L Marks","year":"2012","unstructured":"Marks L (2012) The birth pangs of monoclonal antibody therapeutics: the failure and legacy of Centoxin. MAbs 4(3):403\u2013412","journal-title":"MAbs"},{"key":"18_CR13","first-page":"524","volume":"24","author":"G K\u00f6hler","year":"1992","unstructured":"K\u00f6hler G, Milstein C (1992) Continuous cultures of fused cells secreting antibody of predefined specificity. 1975. Biotechnology 24:524\u2013526","journal-title":"Biotechnology"},{"issue":"4","key":"18_CR14","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.amsu.2014.09.001","volume":"3","author":"JKH Liu","year":"2014","unstructured":"Liu JKH (2014) The history of monoclonal antibody development \u2013 progress, remaining challenges and future innovations. Ann Med Surg 3(4):113\u2013116","journal-title":"Ann Med Surg"},{"issue":"2","key":"18_CR15","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/0022-1759(94)90051-5","volume":"168","author":"RJ Owens","year":"1994","unstructured":"Owens RJ, Young RJ (1994) The genetic engineering of monoclonal antibodies. J Immunol Methods 168(2):149\u2013165","journal-title":"J Immunol Methods"},{"key":"18_CR16","doi-asserted-by":"crossref","unstructured":"Zhao L, Wu Q, Song R, Yun Z (2019) Genetic engineering antibody: principles and application. IOP Conf Ser Mater Sci Eng 612(2)","DOI":"10.1088\/1757-899X\/612\/2\/022045"},{"issue":"3","key":"18_CR17","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/nbt.1791","volume":"29","author":"ARM Bradbury","year":"2011","unstructured":"Bradbury ARM, Sidhu S, D\u00fcbel S, McCafferty J (2011) Beyond natural antibodies: the power of in vitro display technologies. Nat Biotechnol 29(3):245\u2013254","journal-title":"Nat Biotechnol"},{"issue":"9","key":"18_CR18","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/nbt1126","volume":"23","author":"HR Hoogenboom","year":"2005","unstructured":"Hoogenboom HR (2005) Selecting and screening recombinant antibody libraries. Nat Biotechnol 23(9):1105\u20131116","journal-title":"Nat Biotechnol"},{"key":"18_CR19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/978-1-61779-931-0_2","volume":"901","author":"CR Geyer","year":"2012","unstructured":"Geyer CR, McCafferty J, D\u00fcbel S, Bradbury ARM, Sidhu SS (2012) Recombinant antibodies and in vitro selection technologies. Methods Mol Biol 901:11\u201332","journal-title":"Methods Mol Biol"},{"key":"18_CR20","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.copbio.2019.01.012","volume":"60","author":"K Basu","year":"2019","unstructured":"Basu K, Green EM, Cheng Y, Craik CS (2019) Why recombinant antibodies \u2013 benefits and applications. Curr Opin Biotechnol 60:153\u2013158","journal-title":"Curr Opin Biotechnol"},{"key":"18_CR21","doi-asserted-by":"publisher","first-page":"2405954","DOI":"10.1155\/2016\/2405954","volume":"2016","author":"S Khan","year":"2016","unstructured":"Khan S et al (2016) Role of recombinant DNA technology to improve life. Int J Genomics 2016:2405954","journal-title":"Int J Genomics"},{"issue":"3","key":"18_CR22","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1182\/blood.V76.3.562.562","volume":"76","author":"L Borche","year":"1990","unstructured":"Borche L, Lim A, Binet JL, Dighiero G (1990) Evidence that chronic lymphocytic leukemia B lymphocytes are frequently committed to production of natural autoantibodies. Blood 76(3):562\u2013569","journal-title":"Blood"},{"issue":"1","key":"18_CR23","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1084\/jem.169.1.255","volume":"169","author":"ZM Sthoeger","year":"1989","unstructured":"Sthoeger ZM et al (1989) Production of autoantibodies by CD5-expressing B lymphocytes from patients with chronic lymphocytic leukemia. J Exp Med 169(1):255\u2013268","journal-title":"J Exp Med"},{"issue":"5","key":"18_CR24","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/0896-8411(88)90068-6","volume":"1","author":"BM Br\u00f6ker","year":"1988","unstructured":"Br\u00f6ker BM et al (1988) Chronic lymphocytic leukemic (CLL) cells secrete multispecific autoantibodies. J Autoimmun 1(5):469\u2013481","journal-title":"J Autoimmun"},{"issue":"3","key":"18_CR25","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/j.1365-2249.1991.tb05653.x","volume":"83","author":"S Jahn","year":"1991","unstructured":"Jahn S et al (1991) Human hybridomas derived from CDS+ B lymphocytes of patients with chronic lymphocytic leukemia (B-CLL) produce multi-specific natural IgM (kappa) antibodies. Clin Exp Immunol 83(3):413\u2013417","journal-title":"Clin Exp Immunol"},{"issue":"11","key":"18_CR26","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.1016\/j.molimm.2008.03.002","volume":"45","author":"D Siemer","year":"2008","unstructured":"Siemer D, Kurth J, Lang S, Lehnerdt G, Stanelle J, K\u00fcppers R (2008) EBV transformation overrides gene expression patterns of B cell differentiation stages. Mol Immunol 45(11):3133\u20133141","journal-title":"Mol Immunol"},{"issue":"1\u20132","key":"18_CR27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/0022-1759(87)90170-0","volume":"100","author":"K James","year":"1987","unstructured":"James K, Bell GT (1987) Human monoclonal antibody production. Current status and future prospects. J Immunol Methods 100(1\u20132):5\u201340","journal-title":"J Immunol Methods"},{"issue":"6","key":"18_CR28","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1172\/JCI24387","volume":"115","author":"M Herv\u00e9","year":"2005","unstructured":"Herv\u00e9 M et al (2005) Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity. J Clin Invest 115(6):1636\u20131643","journal-title":"J Clin Invest"},{"issue":"23","key":"18_CR29","doi-asserted-by":"publisher","first-page":"3580","DOI":"10.1182\/blood-2014-09-603217","volume":"125","author":"M Gounari","year":"2015","unstructured":"Gounari M et al (2015) Excessive antigen reactivity may underlie the clinical aggressiveness of chronic lymphocytic leukemia stereotyped subset #8. Blood 125(23):3580\u20133587","journal-title":"Blood"},{"issue":"Supplement 1","key":"18_CR30","doi-asserted-by":"publisher","first-page":"9294","DOI":"10.1182\/blood-2022-168728","volume":"140","author":"M Gerousi","year":"2022","unstructured":"Gerousi M et al (2022) Molecular and functional profiling of microenvironmental interactions in splenic marginal zone lymphoma. Blood 140(Supplement 1):9294\u20139295","journal-title":"Blood"},{"key":"18_CR31","doi-asserted-by":"crossref","unstructured":"Iatrou A et al (2023) N-glycosylation of the Ig receptors shapes the antigen reactivity in chronic lymphocytic Leukemia subset #201. J Immunol 211(5)","DOI":"10.4049\/jimmunol.2300330"}],"container-title":["Methods in Molecular Biology","B-Cell Receptor Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-4442-3_18","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T13:15:05Z","timestamp":1741007705000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-4442-3_18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9781071644416","9781071644423"],"references-count":31,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-4442-3_18","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"4 March 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}